Vicebio Ltd (“Vicebio”), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory viruses, today announces its progress in the ongoing VXB-241 bivalent RSV-hMPV Phase 1 (P1) study as well as the appointment of Moncef Slaoui, PhD, and Khurem Farooq to its Board of Directors. Vicebio is progressing into the second stage of its clinical study of VXB-241 and is now enrolling individuals aged 60 years of age and above to evaluate the candidate vaccine’s safety in this...